Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland, Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as part of Featured Clinical Research during the 2025 …